Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–11. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–63. doi:10.1016/s0140-6736(17)31607-0. PMID:Pmc5714293.
   PubMed Web of Science ®Google Scholar
• Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473–88. doi:10.1016/j.ccell.2020.07.005.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022. doi:10.3389/fimmu.2019.02022. PMID:Pmc6718566.
   PubMed Web of Science ®Google Scholar
• Gorabi AM, Hajighasemi S, Sathyapalan T, Sahebkar A. Cell transfer-based immunotherapies in cancer: a review. IUBMB Life. 2020;72(4):790–800. doi:10.1002/iub.2180.
   PubMed Web of Science ®Google Scholar
• Strizova Z, Bartunkova J, Smrz D. The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma. Cancer Immunol Immunother. 2019;68(11):1831–38. doi:10.1007/s00262-019-02359-z.
   PubMed Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19. doi:10.1002/(sici)1096-9896(199909)189:1<12:aid-path431>3.0.co;2-f.
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–99. doi:10.1016/s0140-6736(13)60022-7.
   PubMed Web of Science ®Google Scholar
• Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129–36. doi:10.1016/0092-8674(90)90409-8.
   PubMed Web of Science ®Google Scholar
• Ganti K, Broniarczyk J, Manoubi W, Massimi P, Mittal S, Pim D, Szalmas A, Thatte J, Thomas M, Tomaić V, et al. The human papillomavirus E6 PDZ binding motif: from life cycle to malignancy. Viruses. 2015;7(7):3530–51. doi:10.3390/v7072785. PMID:Pmc4517114.
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934–37. doi:10.1126/science.2537532.
   PubMed Web of Science ®Google Scholar
• Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J Gen Virol. 2013;94(Pt 11):2504–14. doi:10.1099/vir.0.054486-0.
   PubMedGoogle Scholar
• Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, Lee CW, Kim S, Woo JW, Park KS, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317. PMID:PMC4220493 which is developing GX-188E vaccine. The remaining authors declare no competing financial interests. doi:10.1038/ncomms6317.
   PubMed Web of Science ®Google Scholar
• Liao SJ, Deng DR, Zeng D, Zhang L, Hu XJ, Zhang WN, Li L, Jiang XF, Wang CY, Zhou JF, et al. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo. J Huazhong Univ Sci Technolog Med Sci. 2013;33(5):735–42. doi:10.1007/s11596-013-1189-5.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. a preliminary report. N Engl J Med. 1988;319(25):1676–80. doi:10.1056/nejm198812223192527.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–21. doi:10.1126/science.3489291.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575–79. doi:10.1038/s41586-018-0130-2.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–39. doi:10.1200/jco.2008.16.5449. PMID:Pmc2652090.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–57. doi:10.1158/1078-0432.ccr-11-0116. PMID:Pmc3131487.
   PubMed Web of Science ®Google Scholar
• Merhavi-Shoham E, Itzhaki O, Markel G, Schachter J, Besser MJ. Adoptive cell therapy for metastatic melanoma. Cancer J. 2017;23(1):48–53. doi:10.1097/ppo.0000000000000240.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107(3). doi:10.1093/jnci/dju435. PMID:Pmc4565530.
   Google Scholar
• Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–50. doi:10.1200/jco.2014.58.9093. PMID:PMC4417725 online at Author contributions are found at the end of this article.
   PubMed Web of Science ®Google Scholar
• Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200–05. doi:10.1126/science.aak9510. PMID:Pmc6295311.
   PubMed Web of Science ®Google Scholar
• Stevanović S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin Cancer Res. 2019;25(5):1486–93. doi:10.1158/1078-0432.ccr-18-2722. PMID:Pmc6397671.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019;474(4):449–61. doi:10.1007/s00428-018-2484-0. PMID:Pmc6447513.
   PubMed Web of Science ®Google Scholar
• Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48(12):1490–99. doi:10.1038/ng.3692. PMID:Pmc5549141.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer Immunology. the “cancer immunogram”. Science. 2016;352(6286):658–60. doi:10.1126/science.aaf2834.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991. PMID:Pmc5577644.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Chacon JA, Sarnaik AA, Chen JQ, Creasy C, Kale C, Robinson J, Weber J, Hwu P, Pilon-Thomas S, Radvanyi L. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clin Cancer Res. 2015;21(3):611–21. doi:10.1158/1078-0432.ccr-14-1934. PMID:Pmc4315752.
   PubMed Web of Science ®Google Scholar
• Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ Jr. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44–55. doi:10.1158/1078-0432.ccr-13-0945. PMID:Pmc3947326.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18(24):6758–70. doi:10.1158/1078-0432.ccr-12-1177. PMID:Pmc3525747.
   PubMed Web of Science ®Google Scholar
• Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, et al. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med. 2012;4(149):149ra120. doi:10.1126/scitranslmed.3004306. PMID:Pmc6453124.
   PubMed Web of Science ®Google Scholar
• Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother (1991). 2008;31(8):742–51. doi:10.1097/CJI.0b013e31818403d5. PMID:Pmc2614999.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, et al. Randomized selection design trial evaluating CD8±enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013;31(17):2152–59. doi:10.1200/jco.2012.46.6441. PMID:PMC3731980 found at the end of this article.
   PubMed Web of Science ®Google Scholar
• Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother (1991). 2012;35(8):615–20. doi:10.1097/CJI.0b013e31826e8f5f. PMID:4467830.
   PubMed Web of Science ®Google Scholar
• O’-Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010;327(5969):1098–102. doi:10.1126/science.1178334. PMID:2997673.
   PubMed Web of Science ®Google Scholar
• Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Ménoret A, Mittler RS, Gordon SM, Reiner SL, Vella AT, et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol. 2011;187(7):3555–64. doi:10.4049/jimmunol.1101244. PMID:3178659.
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature. 2009;462(7272):510–13. doi:10.1038/nature08511. PMID:2789415.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–45. doi:10.1126/science.1251102.
   PubMed Web of Science ®Google Scholar
• Veatch JR, Lee SM, Fitzgibbon M, Chow IT, Jesernig B, Schmitt T, Kong YY, Kargl J, Houghton AM, Thompson JA, et al. Tumor-Infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest. 2018;128(4):1563–68. doi:10.1172/jci98689. PMID:5873881.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–30. doi:10.1038/s41591-018-0040-8. PMID:6348479.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–62. doi:10.1056/NEJMoa1609279. PMID:5178827.
   PubMed Web of Science ®Google Scholar
• Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell. 2018;173(7):1755–69.e1722. doi:10.1016/j.cell.2018.03.073.
   PubMed Web of Science ®Google Scholar
• Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Szomolay B, Ott S, Dolton G, et al. PD-1(+) polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer. Clin Cancer Res. 2017;23(19):5779–88. doi:10.1158/1078-0432.ccr-16-1692. PMID:7115919.
   PubMed Web of Science ®Google Scholar
• de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Löwik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 2010;70(7):2707–17. doi:10.1158/0008-5472.can-09-4299.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–30.e814. doi:10.1016/j.immuni.2018.03.023. PMID:5982584.
   PubMed Web of Science ®Google Scholar
• Adurthi S, Mukherjee G, Krishnamurthy H, Sudhir K, Bafna UD, Umadevi K, Jayshree RS. Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells. Int J Gynecol Cancer. 2012;22(7):1130–37. doi:10.1097/IGC.0b013e318262aa53.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG. Tumor-infiltrating lymphocyte therapy: addressing prevailing questions. Cancer J. 2015;21(6):450–64. doi:10.1097/ppo.0000000000000162.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annu Rev Immunol. 2019;37:173–200. doi:10.1146/annurev-immunol-042617-053402.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhang AXJ, Chen G, Wu Y, Gu W. Prognostic and therapeutic TILs of cervical cancer-current advances and future perspectives. Mol Ther Oncolytics. 2021;22:410–30. PMID:Pmc8430272. doi:10.1016/j.omto.2021.07.006.
   PubMed Web of Science ®Google Scholar
• Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr., Riley JL, June CH, Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719–30. doi:10.1158/1078-0432.ccr-11-0351. PMID:3612507.
   PubMed Web of Science ®Google Scholar
• Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365–86. doi:10.7150/thno.58390. PMID:Pmc8039952.
   PubMed Web of Science ®Google Scholar
• Ding N, Zou Z, Sha H, Su S, Qian H, Meng F, Chen F, Du S, Zhou S, Chen H, et al. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun. 2019;10(1):1336. doi:10.1038/s41467-019-09296-6. PMID:6430780.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92. doi:10.1093/annonc/mdw168.
   PubMed Web of Science ®Google Scholar
• Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, et al. Multifaceted role of BTLA in the control of CD8(+) T-cell fate after antigen encounter. Clin Cancer Res. 2017;23(20):6151–64. doi:10.1158/1078-0432.ccr-16-1217. PMID:5748156.
   PubMed Web of Science ®Google Scholar
• Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179. PMID:4604472. doi:10.1038/srep15179.
   PubMed Web of Science ®Google Scholar
• Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019;16(1):45–63. doi:10.1038/s41571-018-0075-2. PMID:7096894.
   PubMed Web of Science ®Google Scholar
• Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. Semin Immunopathol. 2019;41(1):49–58. doi:10.1007/s00281-018-0703-z.
   PubMed Web of Science ®Google Scholar
• Gowrishankar K, Birtwistle L, Micklethwaite K. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mamm Genome. 2018;29(11–12):739–56. doi:10.1007/s00335-018-9756-5.
   PubMed Web of Science ®Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(5):273–90. doi:10.1038/nrclinonc.2016.25. PMID:5551685.
   PubMed Web of Science ®Google Scholar
• Frenel JS, Le Tourneau C, O’-Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the Phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–41. doi:10.1200/jco.2017.74.5471.
   PubMed Web of Science ®Google Scholar
• Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology. 2013;139(4):513–22. doi:10.1111/imm.12101. PMID:3719068.
   PubMed Web of Science ®Google Scholar
• Feng YC, Ji WL, Yue N, Huang YC, Ma XM. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. Cancer Manag Res. 2018;10:105–13. PMID:5783151. doi:10.2147/cmar.s152232.
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33. doi:10.1016/j.molmed.2014.10.009. PMID:4282825.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-Regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. doi:10.1126/scitranslmed.3006504. PMID:4136707.
   PubMed Web of Science ®Google Scholar
• Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, et al. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Ann Oncol. 2018;29(7):1575–81. doi:10.1093/annonc/mdy139.
   PubMed Web of Science ®Google Scholar
• Yin H, Guo W, Sun X, Li R, Feng C, Tan Y. Tils and anti-PD1 therapy: an alternative combination therapy for PDL1 negative metastatic cervical cancer. J Immunol Res. 2020;2020:8345235. PMID:Pmc7492938. doi:10.1155/2020/8345235.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K, Truxova I, Skapa P, Laco J, Pecen L, et al. TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. Clin Cancer Res. 2019;25(15):4820–31. doi:10.1158/1078-0432.ccr-18-4175.
   PubMed Web of Science ®Google Scholar
• He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, et al. LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes. J Thorac Oncol. 2017;12(5):814–23. doi:10.1016/j.jtho.2017.01.019.
   PubMed Web of Science ®Google Scholar
• Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology. 2018;7(12):e1502905. doi:10.1080/2162402x.2018.1502905. PMID:6279323.
   PubMed Web of Science ®Google Scholar
• Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine. 2004;23(1):97–113. doi:10.1016/j.vaccine.2003.12.036.
   PubMed Web of Science ®Google Scholar
• Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14(5):1455–63. doi:10.1158/1078-0432.ccr-07-0371. PMID:2879140.
   PubMed Web of Science ®Google Scholar
• Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2(7):616–31. doi:10.1158/2326-6066.cir-14-0027. PMID:4082460.
   PubMed Web of Science ®Google Scholar
• Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 2012;72(16):3997–4007. doi:10.1158/0008-5472.can-12-1377.
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-Term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410–17. doi:10.1200/jco.2007.15.0284.
   PubMed Web of Science ®Google Scholar
• Lövgren T, Wolodarski M, Wickström S, Edbäck U, Wallin M, Martell E, Markland K, Blomberg P, Nyström M, Lundqvist A, et al. Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. Oncoimmunology. 2020;9(1):1792058. doi:10.1080/2162402x.2020.1792058. PMID:Pmc7458624.
   PubMed Web of Science ®Google Scholar
• Song S, Zhang K, You H, Wang J, Wang Z, Yan C, Liu F. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Clin Exp Immunol. 2010;162(1):75–83. doi:10.1111/j.1365-2249.2010.04226.x. PMID:Pmc2990932.
   PubMed Web of Science ®Google Scholar
• Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene. 2007;26(11):1650–55. doi:10.1038/sj.onc.1209950. PMID:3350866.
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249–53. doi:10.1038/nature15520. PMID:4779053.
   PubMed Web of Science ®Google Scholar
• Dan H, Zhang S, Zhou Y, Guan Q. DNA methyltransferase inhibitors: catalysts for antitumour immune responses. Onco Targets Ther. 2019;12:10903–16. PMID:Pmc6913319. doi:10.2147/ott.s217767.
   PubMed Web of Science ®Google Scholar
• Covre A, Coral S, Nicolay H, Parisi G, Fazio C, Colizzi F, Fratta E, Di Giacomo AM, Sigalotti L, Natali PG, et al. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology. 2015;4(8):e1019978. doi:10.1080/2162402x.2015.1019978. PMID:4570131.
   PubMed Web of Science ®Google Scholar
• Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother. 2016;65(7):787–96. doi:10.1007/s00262-015-1776-3.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013;19(29):4808–17. doi:10.3748/wjg.v19.i29.4808. PMID:3732856.
   PubMed Web of Science ®Google Scholar
• Sahin M, Sahin E, Koksoy S. Regulatory T cells in cancer: an overview and perspectives on cyclooxygenase-2 and Foxp3 DNA methylation. Hum Immunol. 2013;74(9):1061–68. doi:10.1016/j.humimm.2013.05.009.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Maksimovic J, Naselli G, Qian J, Chopin M, Blewitt ME, Oshlack A, Harrison LC. Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells. Blood. 2013;122(16):2823–36. doi:10.1182/blood-2013-02-481788. PMID:3798997.
   PubMed Web of Science ®Google Scholar
• Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7). doi:10.3390/ijms18071414. PMID:Pmc5535906.
   Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237–51. doi:10.1038/nrc3237. PMID:3967236.
   PubMed Web of Science ®Google Scholar
• Cao K, Wang G, Li W, Zhang L, Wang R, Huang Y, Du L, Jiang J, Wu C, He X, et al. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene. 2015;34(49):5960–70. doi:10.1038/onc.2015.46. PMID:4672172.
   PubMed Web of Science ®Google Scholar
• Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, Mueller DL, Mescher MF. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol. 2009;183(3):1695–704. doi:10.4049/jimmunol.0900592. PMID:2893405.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhou X, DiSpirito JR, Wang C, Wang Y, Shen H. Epigenetic manipulation restores functions of defective CD8+ T cells from chronic viral infection. Mol Ther. 2014;22(9):1698–706. doi:10.1038/mt.2014.91. PMID:4435497.
   PubMed Web of Science ®Google Scholar
• Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014;5(16):6558–72. doi:10.18632/oncotarget.2289. PMID:Pmc4196144.
   PubMed Web of Science ®Google Scholar
• Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:99–113. PMID:7308208. doi:10.1016/j.semcancer.2019.12.019.
   PubMed Web of Science ®Google Scholar